Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00897468 |
Recruitment Status
:
Active, not recruiting
First Posted
: May 12, 2009
Last Update Posted
: May 17, 2017
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | May 9, 2009 | |||
First Posted Date | May 12, 2009 | |||
Last Update Posted Date | May 17, 2017 | |||
Study Start Date | February 2007 | |||
Actual Primary Completion Date | May 15, 2017 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures |
|
|||
Original Primary Outcome Measures |
|
|||
Change History | Complete list of historical versions of study NCT00897468 on ClinicalTrials.gov Archive Site | |||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Outcome Measures | Not Provided | |||
Original Other Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer | |||
Official Title | Developing In-Vivo Models of Human Breast Cancer | |||
Brief Summary | RATIONALE: Changing the genes in laboratory mice to create a living model of human breast cancer may help doctors learn more about breast cancer. PURPOSE: This research study is developing mouse models of breast cancer using tissue samples that were previously collected from women with breast cancer. |
|||
Detailed Description | OBJECTIVES:
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics. Patients' medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment. |
|||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | breast cancer patients | |||
Condition | Breast Cancer | |||
Intervention |
|
|||
Study Groups/Cohorts | breast cancer patients
Interventions:
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Active, not recruiting | |||
Actual Enrollment |
26 | |||
Original Enrollment | Not Provided | |||
Estimated Study Completion Date | March 2018 | |||
Actual Primary Completion Date | May 15, 2017 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
|
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Senior) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00897468 | |||
Other Study ID Numbers | VICC BRE 0704 P30CA068485 ( U.S. NIH Grant/Contract ) VU-VICC-BRE-0704 |
|||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | A Bapsi Chakravarthy, MD, Vanderbilt-Ingram Cancer Center | |||
Study Sponsor | Vanderbilt-Ingram Cancer Center | |||
Collaborators | National Cancer Institute (NCI) | |||
Investigators |
|
|||
PRS Account | Vanderbilt-Ingram Cancer Center | |||
Verification Date | May 2017 |